| |
|
Combined Environmental Risk Assessment for the
antiviral pharmaceuticals ganciclovir and
valganciclovir in Europe.
Straub JO
Environ Toxicol Chem. 2017 Feb 15.
Abstract
Extended Low-Dose Valganciclovir Is
Effective Prophylaxis Against Cytomegalovirus in
High-Risk Kidney Transplant Recipients With
Near-Complete Eradication of Late-Onset Disease.
Fayek SA, Beshears E, Lieber R,
et
al
Transplant Proc.
2016 Jul-Aug;48(6):2056-2064.e1
Abstract
FULL-TEXT ARTICLE
Valaciclovir to
prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated
vasculitis (CANVAS): study protocol for a randomised controlled trial.
Chanouzas D, Dyall L, Nightingale P, et al
Trials. 2016 Jul 22;17(1):338
Paper
Valganciclovir Administration to Kidney Donors to Reduce the Burden of
Cytomegalovirus and Epstein-Barr Virus Transmission During Transplantation.
Verghese PS, Schmeling DO, Knight JA, et al
Transplantation. 2014 Dec 8
Abstract
FULL-TEXT ARTICLE
Maternal
Valacyclovir and Infant Cytomegalovirus Acquisition: A Randomized Controlled
Trial among HIV-Infected Women.
Roxby AC, Atkinson C,
Asbjörnsdóttir K, et al
PLoS One.
2014 Feb 4;9(2):e87855.
Paper
FULL-TEXT
PDF ARTICLE
Lower incidence of CMV infection and acute rejections with
valganciclovir prophylaxis in lung transplant recipients.
Johansson I, Mårtensson G, Nyström U, et al
BMC Infect Dis.
2013 Dec 10;
Paper
Impact of CMV therapy with
valganciclovir on immune activation and the HIV
viral load in semen and blood: an observational
clinical study.
Shin LY, Sheth PM, Persad D, et al
J Acquir Immune Defic Syndr.
2013 Oct 2
Abstract
Critical analysis of valganciclovir
dosing and renal function on the development of
cytomegalovirus infection in kidney transplantation.
Posadas Salas MA, Taber DJ, Chua E, et al
Transpl Infect Dis.
2013 Sep 9.
Abstract
Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing
Posttransplant
Cytomegalovirus Disease Within the United States.
Blumberg EA, Hauser IA, Stanisic S,
et al
Transplantation.
2010 Nov 8
Abstract |
FULL-TEXT ARTICLE
Valganciclovir for cytomegalovirus prevention in solid organ transplant
patients: an evidence-based reassessment
of safety and efficacy.
Kalil AC, Freifeld AG, Lyden ER, Stoner JA.
PLoS ONE.
2009;4(5):e5512
Paper |
A Multicenter Study of Valganciclovir Prophylaxis up to Day 120 in
CMV-Seropositive Lung Transplant
Recipients.
Monforte V, Lopez C, Santos F, et al
Am J Transplant. 2009 Mar 16.
Abstract
|
Selective low-dose valganciclovir for prevention of cytomegalovirus disease
following kidney
transplantation
Avidan YP, Paul M, Rahamimov R, et al
J Infect. 2008 Jul 30.
Abstract
|
A safety study of oral valganciclovir maintenance treatment ofcytomegalovirus retinitis.
Lalezari J, Lindley J, Walmsley S, et al.
J Acquir Immune Defic Syndr 2002 Aug
1;30(4):392-400
Abstract
Valganciclovir: an advance in cytomegalovirus
therapeutics.
Cocohoba JM, McNicholl IR.
Ann Pharmacother 2002 Jun;36(6):1075-9
Abstract
A controlled trial of valganciclovir as induction therapy for
cytomegalovirus
retinitis..
Martin DF, Sierra-Madero J, Walmsley S, et al
N Engl J Med 2002 Apr 11;346(15):1119-26
Abstract
Oral
valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.
Reusser P
Expert Opin Investig Drugs 2001 Sep;10(9):1745-53
Abstract
Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of
patients
with
acquired immunodeficiency syndrome who are receiving valganciclovir as
induction
and
maintenance therapy for CMV retinitis.
Boivin G, Gilbert C, Gaudreau A, et al.
J Infect Dis 2001 Dec 15;184(12):1598-602
Abstract
Valganciclovir.
Curran M, Noble S.
Drugs 2001;61(8):1145-50 ; discussion 1151-2
Abstract
|
CMV
Main Page
Main
New/Newsworthy
